Company intelligence / Profile preview

SOLBIO

Seoul, South Korea

Ownership: Private
Employees: ~30
Development stage: Other

Overview

SolBio is a South Korean biotechnology company specializing in exosome-based liquid biopsy technology for early disease detection. The company utilizes its proprietary Neu-Exo platform to isolate high-purity exosomes from blood samples, enabling the diagnosis of various cancers and neurodegenerative diseases like Alzheimer's. Their technology aims to provide non-invasive, highly accurate diagnostic solutions that outperform traditional biopsy methods by capturing specific biomarkers with high sensitivity. SolBio is actively expanding its diagnostic pipeline and seeking global partnerships for the commercialization of its early-detection kits.

Therapeutic areas: OncologyNeurology
Modalities: Exosome-based therapyBiologicDevice
Industry: Protein Biomarker Diagnostics

Partnerships

Korea UniversityShinhan Capital

Beyond the preview

Go deeper on SOLBIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOLBIO.

Explore the full profile